Merck & Co. on Tuesday announced that the FDA has approved its Emend injection for the prevention of chemotherapy-induced nausea. The approval covers the drug's 115-mg dosage for use in combination with other treatments for acute and delayed nausea and vomiting due to cancer chemotherapy. The company also said that the injection can replace the 125-mg oral capsule version of Emend.

Full Story:

Related Summaries